Finch Therapeutics is establishing a portfolio of microbiome therapeutics to treat patients with serious and unmet conditions. The microbiome consists of trillions of microbes that live symbiotically on and within humans. Disruption of the microbe composition can increase susceptibility to immune disorders, infections, neurological conditions and cancer. Finch is designing microbiome assets using insights from human microbiota transplantation studies that spans dozens of different conditions. With this information, Finch has established an extensive, multi-layered patent protection for multiple microbiome product strategies including donor-derived and donor-independent which they can now use to generate therapies.

Finch Therapeutics

Founded: 2014
Location: Somerville, MA
Employee range: 1 - 10
Funding: $127.5M IPO Mar 2021; $90M D Sep 2020; $53M Aug 2019; $30M Mar 2018
Investors: OCV Partners, Susquehanna International Group, Trans-Pacific Technology Fund, Avenir Growth Capital, Morgan Noble, Shumway Capital, Willett Advisors

Short description:

Drug notes:

Long description:

Jobs: